Hepatitis Care Coordination in Methadone Treatment

描述（由申请人提供）：静脉注射吸毒者的病毒性肝炎（包括甲型肝炎（HAV）、乙型肝炎B（HBV）和丙型肝炎（HCV））发病率极高，是HCV在美国传播的主要媒介。尽管HCV的医学治疗已大大改善，但吸毒者在预防和护理服务方面遇到了重大障碍。将肝炎预防和医疗保健服务纳入药物滥用治疗计划可能会增加参与和坚持越来越有效的医疗保健。这项随机临床试验将检查肝炎护理协调（HCC）策略的有效性，包括美沙酮维持治疗中阿片类药物使用者的测试，教育，咨询和疫苗接种，与标准测试，教育和咨询（TEC）相比。在HCC模型中，肝炎筛查和甲型肝炎和B肝炎疫苗接种将在现场进行，参与者将在现场接受基于理论的肝炎教育、咨询和病例管理，以促进对HCV评价的依从性;而在TEC中，肝炎筛查在现场进行，但疫苗接种和医疗护理将通过场外转诊提供。主要研究目的是评估HCC干预对HAV和HBV疫苗接种依从性以及与HCV护理提供者初次预约的影响。次要目的包括检查干预对肝炎知识的影响，危险的注射药物使用和性行为，酒精使用;随访丙型肝炎护理的后期阶段;确定干预结果的心理介导因素;估计HCC干预的增量成本，以促进更全面的经济评估，如果证明有效的干预。参与者将是460名（两个研究中心各230名）美沙酮维持治疗患者。他们将被随机分配到HCC或TEC。我们假设那些接受现场HCC的患者更有可能：a）坚持接种HAV和/或HBV疫苗，如所示;和B）对于那些HCV检测阳性的患者，坚持转诊到HCV提供者进行初步诊断评估，而不是TEC组。将在基线、3、9和12个月时进行评估。研究参与者将从两个研究中心的美沙酮维持治疗中招募，增加研究的普遍性。这项研究的结果将对卫生政策规划者具有巨大价值，并将为实施改善针对吸毒者的肝炎服务的举措提供信息。

DESCRIPTION (provided by applicant): Intravenous drug users have extremely high rates of viral hepatitis including hepatitis A (HAV), hepatitis B (HBV), and hepatitis C (HCV) and are the major vector of spread of HCV in the U.S. Although medical treatment of HCV has improved considerably, drug users experience significant barriers to prevention and care services. Integrating hepatitis prevention and health care services into drug abuse treatment programs may increase engagement in and adherence to increasingly effective medical care. This randomized clinical trial will examine the effectiveness of a strategy of Hepatitis Care Coordination (HCC) consisting of testing, education, counseling and vaccination for opioid users in methadone maintenance treatment compared with standard Testing, Education, and Counseling (TEC). In the HCC model, hepatitis screening and hepatitis A and B vaccination will be done on site and participants receive on site theory-based hepatitis education, counseling, and case management to promote adherence to HCV evaluation; whereas in TEC hepatitis screening is done on site, but vaccination and medical care will be provided by off site referral. Primary study aims are to assess the impact of the HCC intervention on adherence to HAV and HBV vaccination and attendance at an initial appointment with a HCV care provider. Secondary aims include examining the effect of the intervention on knowledge of hepatitis, risky injection drug use and sexual behaviors, alcohol use; follow-up with later stages of hepatitis C care; to identify psychological mediators of intervention outcomes; and to estimate the incremental cost of the HCC intervention to facilitate fuller economic evaluations of the intervention if proven effective. Participants will be 460 (230 from each of two sites) methadone maintenance patients. They will be randomly assigned to either HCC or TEC. We hypothesize that those receiving on site HCC will be more likely to: a) adhere to vaccination for HAV and/or HBV, as indicated; and b) for those who test HCV positive, to adhere to referral to an initial diagnostic evaluation with a HCV provider than the TEC group. Assessment will occur at baseline, 3, 9, and 12 months. Study participants will be recruited from methadone maintenance treatment at two sites, increasing the generalizability of the study. Findings from this study would be of immense value to health policy planners and would inform the implementation of initiatives to improve hepatitis services targeted to drug users.